Benefits
Small average weight difference in konjac fiber trials
Pooling 14 randomized trials in 531 people, konjac glucomannan was associated with about 0.79 kg (under 2 lbs) more weight loss than placebo, a small effect. In the 83 person, 60 day trial usually cited for this brand, there was no statistically significant difference between the fiber and placebo for body weight or body fat when all randomized participants were compared. The 5.5 lbs figure does not come from any published trial of this ingredient, and no published weight study has used LuraLean specifically.
Cholesterol and LDL reduction
This is the strongest part of the evidence, and it belongs to konjac fiber generally rather than to this brand. A pooled analysis of 14 randomized trials (531 people) found total cholesterol about 19 mg/dL lower and LDL about 16 mg/dL lower than placebo. A second pooled analysis of 12 trials (370 people) found roughly a 10 percent LDL reduction at about 3 g a day. In the 83 person, 60 day study often quoted for this brand, cholesterol changes reached significance only in the subgroup judged to have taken the product as directed, not in the group as a whole.
Blood glucose lowering effects
The glucose studies referred to in advertising review documents were submitted by the marketer and were never published, so their methods and results cannot be checked by anyone else. The published evidence is on konjac glucomannan in general: a pooled analysis of 14 trials found fasting glucose about 7 mg/dL lower, and a randomized trial in people already diagnosed with type 2 diabetes found a 5.7 percent fall in fructosamine, a marker of recent blood sugar control. Viscous fiber slows how quickly carbohydrate is absorbed. This is not a treatment for diabetes, and the diabetes trial does not tell you what the fiber does in a healthy person.
Fullness from a fiber that thickens in the stomach
Konjac fiber soaks up water and forms a thick gel in the stomach, which may add to a feeling of fullness alongside a reduced calorie diet. The 200 times expansion number comes from the supplier rather than from a published measurement, and no published trial has measured appetite or fullness using LuraLean. The same swelling is the reason this fiber has to be taken with a full glass of water.
Viscosity advantage is a supplier claim, not a tested one
The supplier states that its extraction produces a high purity fiber with higher molecular weight and thickness than other konjac products, and that it keeps that thickness as it travels through the gut. That is a reasonable idea, because thickness is what slows digestion, but no published study has compared this product head to head against another glucomannan. There is no evidence that it works better, and no superior weight loss or metabolic result has been documented for it.
Mannanase removal — extended GI activity
The supplier says its process removes mannanase, an enzyme that can break glucomannan down before it is ever swallowed. If so, that is a plausible reason to expect a more consistent product. It has not been tested in people, and no trial has shown this ingredient performing better than ordinary glucomannan.
Lipid binding (fecal cholesterol excretion)
Viscous fiber binds bile acids and some dietary fat in the gut so more of it leaves in the stool, which is the usual explanation for the cholesterol drops seen in konjac glucomannan trials. It does not act like a magnet for calories. The advertising self-regulation panel that reviewed products with this ingredient specifically required the marketer to change the fat absorption claim, because fullness rather than blocked fat was the supportable mechanism.
Carbohydrate absorption modulation
Viscous soluble fiber slows how quickly carbohydrate is digested and absorbed, which can blunt the rise in blood sugar after a meal. This has been measured with konjac glucomannan generally, not with LuraLean. The clearest human data comes from a randomized trial in people already living with type 2 diabetes, so it describes what was studied in patients rather than what the fiber does for a healthy person.
Mechanism of action
Gastric expansion satiety
Konjac fiber absorbs water and swells into a gel in the stomach. Stretching the stomach wall is thought to send fullness signals that reduce how much is eaten afterwards. The 200 times figure is a supplier claim rather than a measured clinical finding, and no published trial has confirmed reduced food intake with this specific product.
Viscosity maintenance through GI tract
Higher molecular weight fibers tend to stay thicker as they move through the gut, and thickness is what slows digestion, so the idea is sound in principle. The claim that this product holds its thickness better than others comes from the supplier. There are no clinical studies comparing it with generic glucomannan, so no superior performance has been shown.
Bile acid sequestration
Soluble viscous fiber binds bile acids in the intestine, preventing their reabsorption. The liver then uses cholesterol to make replacement bile acids, which can lower cholesterol in the blood. This is the accepted explanation for the LDL reductions measured in randomized trials of konjac glucomannan as a fiber, none of which used this particular brand.
Carbohydrate absorption delay
Viscous fiber slows stomach emptying and movement through the small intestine, which delays carbohydrate absorption. Glucose enters the bloodstream more gradually, so the rise after a meal is smaller. Much of this work was done in people with type 2 diabetes; anyone taking blood sugar medicine should speak to their doctor before adding a fiber supplement, since doses may need adjusting.
Fecal fat binding
Some fat and bile acid is trapped in the fiber gel and passed out in the stool, but the number of calories involved is small. Fullness, not blocked fat absorption, is the main proposed mechanism, and the advertising review panel that examined this ingredient made the marketer drop the fat absorption claim.
Clinical trials
Randomized, double blind, placebo controlled study of generic konjac glucomannan, 3 g a day together with 300 mg calcium carbonate, for 60 days. Body composition was measured by DEXA scan. This was not a study of LuraLean, and the paper does not mention the brand.
83 overweight adults, of whom 80 completed the 60 day study.
Counting everyone who was randomized, there were no statistically significant differences between the fiber and placebo groups on any of the DEXA body composition measures or the blood tests. Fat loss only became significant after the researchers re-sorted participants into compliant and partly compliant groups, an after the fact analysis that undoes the protection randomization provides and tends to favor the product. The authors say as much, noting the positive outcomes were not visible until corrections for compliance were applied, and the paper's own title limits the finding to compliant adults. The 5.5 lbs and 21.7 mg/dL figures used in marketing do not come from this trial.
The Electronic Retailing Self-Regulation Program is an advertising industry review body, not a government regulator and not a research study. It examined marketing claims for products containing this ingredient. The studies the marketer handed over were never published in a medical journal, so their design, dose, sample size and results cannot be checked by anyone outside that review.
Not applicable. This was a review of advertising claims and unpublished company data, not a study in people.
The panel allowed general fullness and weight loss wording on the basis of unpublished company data, and required the fat absorption claim to be changed because fullness, not blocked fat, was the supportable mechanism. Unpublished data reviewed by an advertising panel is weak evidence and should not be read as the equivalent of a published, peer reviewed clinical trial.
The real evidence base belongs to konjac glucomannan as a fiber, and is best summarized by two meta-analyses: 14 randomized trials in 531 people (2008) and 12 randomized trials in 370 people (2017). The figure of more than 60 trials is a supplier talking point rather than a published, counted total. None of the trials in either analysis used LuraLean.
Adults across randomized trials of konjac glucomannan, including people with raised cholesterol and people with type 2 diabetes.
Pooled results for konjac glucomannan versus placebo: total cholesterol about 19 mg/dL lower, LDL about 16 mg/dL lower, triglycerides about 11 mg/dL lower, fasting glucose about 7 mg/dL lower, and body weight about 0.79 kg (under 2 lbs) lower. The 2017 analysis found roughly a 10 percent LDL reduction at about 3 g a day. The lipid effect is the strongest and most consistent finding; the weight effect is small. Not every trial is positive: an 8 week trial in overweight and moderately obese adults found no significant weight loss difference against placebo (NCT00613600). Results vary with the source, molecular weight, processing and timing of the fiber.